Outlook Therapeutics (OTLK) Minority Interest (2015 - 2016)
Outlook Therapeutics (OTLK) reported Minority Interest of $17.4 million for Q1 2016, up 12.77% quarter-over-quarter from $15.4 million in Q3 2015.
Outlook Therapeutics (OTLK) Minority Interest (2015 - 2016) Analysis & Trends
Outlook Therapeutics (OTLK) has 2 years of Minority Interest data on file, last reported at $17.4 million in Q1 2016.
- Minority Interest for Q1 2016 came in at $17.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2016 was $17.4 million (changed N/A YoY), and the FY2015 annual result was $15.4 million, changed N/A from the prior year.
- Minority Interest rose to $17.4 million in Q1 2016 per OTLK's latest filing, from $15.4 million in the prior quarter.
- Over five years, Minority Interest peaked at $17.4 million in Q1 2016 and troughed at $15.4 million in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 17.40 Mn |
| Sep 30, 2015 | 15.43 Mn |